Levoatriocardinal Vein With Multiple Ventricular Septal Defects and Without Left-Sided Valvular Atresia

2021 ◽  
Vol 12 (1) ◽  
pp. 128-130
Author(s):  
Kartik Patel ◽  
Deepti Kakkar ◽  
Chandrasekaran Ananthnarayan ◽  
Ravi Patel ◽  
Dinesh Patel ◽  
...  
Keyword(s):  
Mitral Regurgitation ◽  
Ventricular Septal Defect ◽  
Atrial Septal Defect ◽  
Septal Defect ◽  
Ventricular Septal Defects ◽  
Muscular Ventricular Septal Defect ◽  
Septal Defects

Levoatriocardinal vein without left-sided valvular atresia is rare. We hereby present an image of the levoatriocardinal vein in a patient with multiple muscular ventricular septal defect with small atrial septal defect and mitral regurgitation.

Hybrid perventricular muscular ventricular septal defect closure using the new multi-functional occluder

2020 ◽  
Vol 30 (10) ◽  
pp. 1517-1520
Author(s):  
Raymond N. Haddad ◽  
Régis Gaudin ◽  
Damien Bonnet ◽  
Sophie Malekzadeh-Milani
Keyword(s):  
Ventricular Septal Defect ◽  
Septal Defect ◽  
Transcatheter Closure ◽  
Ventricular Septal Defects ◽  
Small Children ◽  
New Device ◽  
Muscular Ventricular Septal Defect ◽  
Septal Defects ◽  
Ventricular Septal Defect Closure ◽  
Technical Features

AbstractThe hybrid perventricular approach for the closure of trabecular ventricular septal defects is an attractive treatment modality for small children. Worldwide experience has shown that procedure success is influenced by the defect anatomical accessibility, operators’ expertise, and device technical features. In May 2018, a new promising device, the KONAR-Multi-functional™ ventricular septal defect occluder (Lifetech, Shenzhen, China), obtained CE-marking for septal defect transcatheter closure after the first-in-man implantation in 2013. Herein, this is the first report of successful perventricular closure of ventricular septal defect using this new device in a child with significant co-morbidities.

Spontaneous closure of muscular ventricular septal defect identified by echocardiography in neonates

1998 ◽  
Vol 8 (4) ◽  
pp. 500-505 ◽  
Author(s):  
Zhong-Dong Du ◽  
Nathan Roguin ◽  
Xing-Jian Wu
Keyword(s):  
Natural History ◽  
Ventricular Septal Defect ◽  
Septal Defect ◽  
Spontaneous Closure ◽  
Ventricular Septal Defects ◽  
Muscular Ventricular Septal Defect ◽  
Septal Defects ◽  
Multiple Defects ◽  
Single Defect ◽  
History Of

AbstractMuscular ventricular septal defects were diagnosed by echocardiography in 97 neonates within 7 days of birth. In 82 of the neonates (84.5%), the defect was solitary, while 15 had multiple defects. The solitary defects was located at mid-septal, apical, anterior and inlet locations in 42 (51.2%), 21 (25.6%), 14 (17.1%) and 5 (6.1%) neonates, respectively. Multiple defects occurred in the apical, anterior and mid-septal areas. The diameter of the solitary defects ranged from 1 to 6 mm (2.3 ± 0.8 mm), while the multiple lesions were 1 to 4 mm in diameter (2.1 2.3 ± 0.8 mm 0.8 mm) in 28 instances in which they could measured. It proved possible to follow 79 of the patients for period of 10 to 13 months. The defects closed spontaneously in 56 (84.8%) of 66 patients with a single defect, and in 7 (53.8%) of 13 of those with multiple defects (P<0.05). For the solitary defects, the position and size were factors determining the likelihood and speed of closure. Defects located at the apical septum, or defects larger than 4 mm in diameter, closed slowly and at a later stage. Echocardiography is an useful technique in establishing of natural history of muscular ventricular septal defects encountered in neonates.

Fulminant cytomegalovirus myocarditis in an infant with concomitant large atrial and ventricular septal defects: medical intervention strategy for functional cardiac regeneration

2018 ◽  
Vol 29 (3) ◽  
pp. 277-279
Author(s):  
Roland Schrewe ◽  
Anoosh Esmaeili ◽  
Kachina Behnke-Hall ◽  
Dietmar Schranz
Keyword(s):  
Heart Failure ◽  
Ventricular Septal Defect ◽  
Atrial Septal Defect ◽  
Septal Defect ◽  
Young Infant ◽  
Intervention Strategy ◽  
Disease Process ◽  
Medical Intervention ◽  
Ventricular Septal Defects ◽  
Septal Defects

AbstractA cytomegalovirus-associated heart failure in a young infant with atrial and ventricular septal defects is reported in this case report. The patient recovered by an anti-congestive and anti-viral therapy with an extra percutaneous transcatheter treatment strategy. In the context of bi-ventricular predominant right heart failure associated with supra-systemic pulmonary hypertension, the already closed arterial duct was re-opened and stented to unload the right ventricle and thereby augment the systemic blood flow. Either the left-to-right shunting atrial septal defect or bi-directional shunting ventricular septal defect was involved in the disease process and was not able to avoid global heart failure. After clinical improvement, the stented duct was shunted left-to-right and was occluded with an ADO-II-AS. During the same procedure the atrial septal defect was closed with an Amplatzer-ASD occluder, while the peri-membranous ventricular septal defect was closed with an ADO-II occluder 2 months later.

Percutaneous closure of multiple ventricular septal defects: simultaneous use of muscular ventricular septal defect device and Multi-Fenestrated Septal Occluder – “Cribriform” to close residual ventricular septal defects after complex cardiac surgery in a child

2016 ◽  
Vol 27 (1) ◽  
pp. 181-183
Author(s):  
Shreesha S. Maiya ◽  
Smruti V. Patel ◽  
Chinnaswamy Reddy ◽  
Suresh V. Pujar
Keyword(s):  
Ventricular Septal Defect ◽  
Pulmonary Artery ◽  
Septal Defect ◽  
Pulmonary Artery Stenosis ◽  
Ventricular Septal Defects ◽  
Muscular Ventricular Septal Defect ◽  
Septal Defects ◽  
Right Pulmonary Artery ◽  
Occluder Device ◽  
Blalock Taussig Shunt

AbstractA male child, with d-transposition of great arteries, a large perimembranous ventricular septal defect, multiple additional ventricular septal defects, small muscle-bound right ventricle, and severe pulmonary stenosis with confluent, moderate-sized branch pulmonary arteries, underwent an emergency right modified Blalock–Taussig shunt on day 15 of life and réparation à l’étageventriculaire procedure with ventricular septal defect closure with takedown of the Blalock–Taussig shunt at 2.5 years of age. On follow-up, he showed a moderate residual upper ventricular septal defect and multiple apical ventricular septal defects, mild mid-right pulmonary artery stenosis, free pulmonary regurgitation, and right ventricular dysfunction. Surgical re-intervention was deemed extremely risky, the upper muscular ventricular septal defect was closed using an 8-mm Amplatzer Muscular Ventricular Septal Defect Occluder Device, and an 18 mm Amplatzer Multi-Fenestrated Septal Occluder – Cribriform was used for the multiple apical muscular ventricular septal defects. After 1 year, his right pulmonary artery stenosis worsened, for which right pulmonary artery angioplasty was carried out using an 8×20 mm cutting balloon followed by a 10×20 mm Tyshak II balloon. This is the only case reported for the paediatric age group using a cribriform septal occluder device for percutaneous closure of multiple apical ventricular septal defects.

Does N-terminal pro-brain natriuretic peptide correlate with measured shunt fraction in children with septal defects?

2015 ◽  
Vol 26 (3) ◽  
pp. 469-476
Author(s):  
Abdullah Ozyurt ◽  
Ali Baykan ◽  
Mustafa Argun ◽  
Ozge Pamukcu ◽  
Kazim Uzum ◽  
...  
Keyword(s):  
Ventricular Septal Defect ◽  
Brain Natriuretic Peptide ◽  
Atrial Septal Defect ◽  
Natriuretic Peptide ◽  
Significant Positive Correlation ◽  
Septal Defect ◽  
Ventricular Septal Defects ◽  
Positive Correlation ◽  
Haemodynamic Parameters ◽  
Septal Defects

AbstractBackgroundThe aim of this study was to investigate the potential role of N-terminal pro-brain natriuretic peptide in the assessment of shunt severity and invasive haemodynamic parameters in children with atrial septal defects and ventricular septal defects.MethodsThis is a prospective, controlled (n:62), observational study. Correlation analysis was performed between N-terminal pro-brain natriuretic peptide levels and various invasive haemodynamic measurements in 127 children (ventricular septal defect: 64; atrial septal defect: 63). A ratio of pulmonary to systemic blood flow (Qp/Qs⩾1.5) was considered to indicate a significant shunt.ResultsStatistically significant relationship was found between the mean N-terminal pro-brain natriuretic peptide values of the patients, with Qp/Qs⩾1.5 in both defect types and control group. For ventricular septal defect, N-terminal pro-brain natriuretic peptide level⩾113.5 pg/ml was associated with high specificity and sensitivity for determining the significant shunt. In addition, the cut-off point for determining the significant shunt for atrial septal defect was 57.9 pg/ml. Significant positive correlation was found between all invasive haemodynamic parameters and N-terminal pro-brain natriuretic peptide levels in patients with ventricular septal defects. Whereas significant positive correlation was found only between mean pulmonary artery pressure, right ventricular end-diastolic pressure, and systemic pressure to pulmonary pressure ratio and N-terminal pro-brain natriuretic peptide levels in patients with atrial septal defects.ConclusionOur study demonstrated that the N-terminal pro-brain natriuretic peptide measurements could be used as a supporting parameter in determining significance of the shunt.

Occlutech® muscular ventricular septal defect device: the first reported human use

2016 ◽  
Vol 26 (7) ◽  
pp. 1448-1451 ◽  
Author(s):  
Gareth J. Morgan
Keyword(s):  
Ventricular Septal Defect ◽  
Septal Defect ◽  
Percutaneous Closure ◽  
Significant Benefit ◽  
Defect Closure ◽  
Ventricular Septal Defects ◽  
Muscular Ventricular Septal Defect ◽  
Septal Defects ◽  
Human Use

AbstractPercutaneous closure of muscular ventricular septal defects has been well described and has not attracted the same controversy or scrutiny as perimembranous defect closure. Therefore, the development of specifically designed devices has been limited. We report the first use of the Occlutech® muscular ventricular septal defect device. Does its design add any significant benefit?

Sign in / Sign up

Export Citation Format

Share Document